VRTX
VERTEX PHARMACEUTICALS INC / MA
Latest close $484.83 as of Aug 5, 2026
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred
from changes in reported shares when available; it is not a list of individual trades or exact execution prices.
Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
Free access includes current parsed ownership filings, reported share changes, and ownership-percentage changes.
Significance scoring, disclosure-speed analysis, confirmation/divergence signals, and signal alerts require Investor or Pro.
Compare plans.
Beneficial ownership filing history
Showing 3 of 5 parsed filing(s) · 2 older require more history access| Holder | Observed / filed | Reported change | Shares | Ownership | Observation | Filing | Latest |
|---|---|---|---|---|---|---|---|
| Capital Research Global Investors CIK0001422848 | Mar 31, 2026 observed May 14, 2026 filed · 44d Schedule 13G amendment | Reported accumulation | 254.0M +315.4K | 12.00% 0.00 pts | $446.54 | $450.41 | $484.83 |
| Vanguard Capital Management CIK0002100119 | Mar 31, 2026 observed Apr 30, 2026 filed · 30d Initial Schedule 13G | Initial Schedule 13G | 19.0M | 12.00% | $446.54 | $427.38 | $484.83 |
| Vanguard Group CIK0000102909 | Mar 13, 2026 observed Mar 27, 2026 filed · 14d Schedule 13G amendment | Earliest Schedule 13G amendment found | 11 | 12.00% | $469.34 | $433.07 | $484.83 |